Norges Bank Syndax Pharmaceuticals Inc Transaction History

Norges Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$14.52 - $21.77 $2.73 Million - $4.1 Million	-188,200 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $3.49 Million - $4.44 Million	169,100 New	169,100 $4.3 Million
Q3 2022 Nov 13, 2023	BUY	$18.51 - $24.79 $3.48 Million - $4.67 Million	188,200 New	188,200 $4.52 Million
Q1 2022 May 12, 2023	BUY	$14.84 - $22.15 $4.69 Million - $6.99 Million	315,800 Added 186.75%	484,900 $8.43 Million
Q1 2022 May 09, 2022	SELL	$14.84 - $22.15 $7.2 Million - $10.7 Million	-484,900 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$15.23 - $22.47 $7.39 Million - $10.9 Million	484,900 New	484,900 $10.6 Million

230

90M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $792M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.